DDInter1042 DDInter840
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Granisetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Granisetron {u} (Compound) resembles {v} (Compound) Atropine
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
Granisetron {u} (Compound) upregulates {v} (Gene) CASP10
Granisetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Granisetron {u} (Compound) downregulates {v} (Gene) HSPA1A
Granisetron {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Granisetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Granisetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Granisetron (Compound) resembles Hyoscyamine (Compound)
Granisetron (Compound) resembles Atropine (Compound)
Granisetron (Compound) binds CYP3A4 (Gene)
Granisetron (Compound) upregulates CASP10 (Gene)
Granisetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Granisetron (Compound) downregulates HSPA1A (Gene)
Granisetron (Compound) causes Hepatic enzyme increased (Side Effect)
Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Granisetron may cause a minor interaction that can limit clinical effects when taken with Modafinil
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib